US 10669303
Compositions and methods directed to treating liver fibrosis
granted A61PA61P1/16A61P19/04
Quick answer
US patent 10669303 (Compositions and methods directed to treating liver fibrosis) held by Alnylam Pharmaceuticals, Inc. expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Jun 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61P, A61P1/16, A61P19/04, A61P29/00, A61P43/00